Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM).

8013Background: SEL, an oral, first-in-class inhibitor of XPO1showed activity in clinical trials for hematologic malignancies. SEL inhibits DNA damage repair and exhibits marked synergywith doxor...